undamentalytics Newsletter
Sign in

60 Degrees Pharmaceuticals, Inc. (SXTP) stock

Add to watchlist

Add holding +

NASDAQ: SXTP Nasdaq Pharmaceuticals

C Fundamentals grade

60 Degrees Pharmaceuticals, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: free cash flow after stock pay is not positive. How we value companies.

60 Degrees Pharmaceuticals, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling4 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds4 adding, 6 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter 60 Degrees Pharmaceuticals files

Where 60 Degrees Pharmaceuticals stands after its latest 10-Q

60 Degrees Pharmaceuticals has little or no product revenue yet; it used $9m of cash in the twelve months to June 2026. That growth ranks 4 of 47 among the pharmaceuticals companies we cover. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 4 of our 6 financial-health checks.

Our models give no value for 60 Degrees Pharmaceuticals at present, so past values are not shown.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

60 Degrees Pharmaceuticals, Inc.'s trailing-twelve-month revenue grew 73.2% year on year, with a free-cash-flow margin of -800.6%. Where it stands out: change in growth rate of +22.3pp ranks 5 of 74 pharmaceuticals companies we cover. Where it lags: free-cash-flow margin of -800.6% ranks 69 of 74 pharmaceuticals companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 38.3% while net income fell 3.8%: a 35pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 73.2% over the last 12 months, against a median of 10.0% for pharmaceuticals companies we cover.
  • Growth speeding up. The growth rate is 22.3 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 425.8 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -774.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -800.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 37.2% of revenue, against a median of 3.6% for pharmaceuticals companies we cover: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 199% and a beta of 2.1 against the S&P 500.
  • Gross margin slipping. Gross margin is down 25.5 points on a year ago.
  • Below peers: days sales outstanding. Days sales outstanding of 186 days ranks 53 of 59 pharmaceuticals companies we cover (median 72 days).

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$0.86 against an average estimate of -$0.89: beat by 3.8%
Revenue
$0m, up 106.0% on a year earlier

60 Degrees Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.6%
  • 1 week+4.4%
  • 1 month-34.8%
  • This year-55.4%
  • 1 year-83.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.1M
Operating margin
-774.9%
Net margin
-729.9%

Growth

Revenue growth
+73.2%
Change in growth rate
+22.3 pts

Cash

Free cash flow (TTM)
-$8.9M
FCF margin
-800.6%
Stock pay % of revenue
37.2%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Announcement
  6. Shareholder vote
  7. Agreement
  8. Announcement
  9. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

60 Degrees Pharmaceuticals, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

Valuation models

We value 60 Degrees Pharmaceuticals, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.6 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — 0 Does not apply: no positive value
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare 60 Degrees Pharmaceuticals, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202320242025
Share price$244.80$25.80$2.03
Market value$16m$3m$1m
+ Net debt (− = net cash)−$675912−$2m−$1m
Enterprise value$16m$1m$4579
Multiples
Price / sales 64.0x4.8x1.4x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.45 +69% $1m −1%
Next −$3.58 −4% $2m +70%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −56.2% on 90 days ago. In the last 30 days, 0 analysts raised 60 Degrees Pharmaceuticals, Inc.'s forecast and 1 cut it.

Consensus EPS forecast 60 Degrees Pharmaceuticals, Inc., last 90 days
−$8.00 −$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$7.88 Current fiscal year, 60 days ago: −$7.88 Current fiscal year, 30 days ago: −$3.18 Current fiscal year, 7 days ago: −$3.18 Current fiscal year, Now: −$3.45 −$3.45

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal year
90 days ago −$7.88
60 days ago −$7.88
30 days ago −$3.18
7 days ago −$3.18
Now −$3.45

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.89 −$0.86 +3.8%
Mar 2026 −$0.99 −$1.21 −22.6%
Dec 2025 −$2.00 −$8.17 −308.6%
Sept 2025 −$1.84 −$2.53 −37.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026
Buy150%
Hold150%
Sell00%

Monthly trend

  1. Oct 2026112

Counts of recommendations published by analysts covering 60 Degrees Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.9%
of tradable shares
Days to cover
0.64
at average volume
Short interest, 1 month
−37%
to October 15, 2026
Held by institutions
21%
of shares
Held by insiders
19.4%
of shares
Employees
3
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202420252026 to date
Return
SXTP−90%−92%−55%
Industry peers (median)−2%+9%−12%
S&P 500+25%+18%+11%
Months that ended higher
SXTP25%33%27%
S&P 50075%75%46%
Largest fall from a high during the year
SXTP−95%−93%−86%
S&P 500−8%−19%−9%

Worst fall since July 12, 2023: 100% from July 12, 2023 to October 27, 2026. Getting back needed a 151684% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.74 – $5.36
From 52-week high
−83.1%
vs 50-day average
−10.0%
vs 200-day average
−48.8%
Volatility (1 year)
199%
Beta vs S&P 500
2.15

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

60 Degrees Pharmaceuticals, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) 60 Degrees Pharmaceuticals, Inc.
$0 $500K $1M $1.5M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $90.7K Revenue (TTM), FY23 Q4: $253.6K Revenue (TTM), FY24 Q1: $342.1K Revenue (TTM), FY24 Q2: $407.5K Revenue (TTM), FY24 Q3: $491.6K Revenue (TTM), FY24 Q4: $607.6K Revenue (TTM), FY25 Q1: $665.5K Revenue (TTM), FY25 Q2: $641.4K Revenue (TTM), FY25 Q3: $943.7K Revenue (TTM), FY25 Q4: $1M Revenue (TTM), FY26 Q1: $1M Revenue (TTM), FY26 Q2: $1.1M $1.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $90.7K
FY23 Q4 $253.6K
FY24 Q1 $342.1K
FY24 Q2 $407.5K
FY24 Q3 $491.6K
FY24 Q4 $607.6K
FY25 Q1 $665.5K
FY25 Q2 $641.4K
FY25 Q3 $943.7K
FY25 Q4 $1M
FY26 Q1 $1M
FY26 Q2 $1.1M
Revenue growth, TTM YoY 60 Degrees Pharmaceuticals, Inc.
0% 200% 400% 600% FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 Revenue growth, TTM YoY, FY24 Q1: 76.9% Revenue growth, TTM YoY, FY24 Q2: 96.2% Revenue growth, TTM YoY, FY24 Q3: 441.9% Revenue growth, TTM YoY, FY24 Q4: 139.6% Revenue growth, TTM YoY, FY25 Q1: 94.5% Revenue growth, TTM YoY, FY25 Q2: 57.4% Revenue growth, TTM YoY, FY25 Q3: 92.0% Revenue growth, TTM YoY, FY25 Q4: 65.5% Revenue growth, TTM YoY, FY26 Q1: 50.9% Revenue growth, TTM YoY, FY26 Q2: 73.2% 73.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 76.9%
FY24 Q2 96.2%
FY24 Q3 441.9%
FY24 Q4 139.6%
FY25 Q1 94.5%
FY25 Q2 57.4%
FY25 Q3 92.0%
FY25 Q4 65.5%
FY26 Q1 50.9%
FY26 Q2 73.2%
Operating margin (TTM) 60 Degrees Pharmaceuticals, Inc.
-6000% -4000% -2000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -4348.8% Operating margin (TTM), FY23 Q4: -2032.8% Operating margin (TTM), FY24 Q1: -1621.4% Operating margin (TTM), FY24 Q2: -2195.5% Operating margin (TTM), FY24 Q3: -1941.3% Operating margin (TTM), FY24 Q4: -1599.0% Operating margin (TTM), FY25 Q1: -1545.4% Operating margin (TTM), FY25 Q2: -1200.7% Operating margin (TTM), FY25 Q3: -838.0% Operating margin (TTM), FY25 Q4: -771.8% Operating margin (TTM), FY26 Q1: -791.2% Operating margin (TTM), FY26 Q2: -774.9% -774.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -4348.8%
FY23 Q4 -2032.8%
FY24 Q1 -1621.4%
FY24 Q2 -2195.5%
FY24 Q3 -1941.3%
FY24 Q4 -1599.0%
FY25 Q1 -1545.4%
FY25 Q2 -1200.7%
FY25 Q3 -838.0%
FY25 Q4 -771.8%
FY26 Q1 -791.2%
FY26 Q2 -774.9%
FCF margin (TTM) 60 Degrees Pharmaceuticals, Inc.
-1500% -1000% -500% 0% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 FCF margin (TTM), FY25 Q2: -1002.6% FCF margin (TTM), FY25 Q3: -726.4% FCF margin (TTM), FY25 Q4: -695.1% FCF margin (TTM), FY26 Q1: -812.8% FCF margin (TTM), FY26 Q2: -800.6% -800.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY25 Q2 -1002.6%
FY25 Q3 -726.4%
FY25 Q4 -695.1%
FY26 Q1 -812.8%
FY26 Q2 -800.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 1 1 1
Gross profit −0 −0 0 0 0
EBITDA −2 −5 −10 −8 −9
Operating income −2 −5 −10 −8 −9
Net income −6 −4 −8 −7 −8
Diluted EPS −$93.96 −$59.18 −$74.17 −$11.73 —
Growth (year on year)
Revenue — +13.6% +139.6% +65.5% +73.2%
Margins
Gross margin −93.7% −87.1% 36.7% 22.3% 19.4%
EBITDA margin −771.8% <−999% <−999% −767.3% −769.4%
Operating margin −784.2% <−999% <−999% −771.6% −774.9%
Net margin <−999% <−999% <−999% −732.5% −729.9%
Free-cash-flow margin — <−999% −946.7% −695.1% −800.6%
Cash flow
Cash from operations −1 −5 −6 −7 −9
Capital spending — 0 0 0 0
Free cash flow — −5 −6 −7 −9
Stock-based pay 0 0 4 0 0
Free cash flow after stock pay — −5 −9 −7 −9
Balance sheet
Cash 0 2 2 2 1
Total debt 17 1 0 0 0
Net debt (negative = net cash) 17 −1 −2 −1 −1
Diluted shares — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $4m
Short-term assets $4mLonger-term assets $1m
What it owes, and who funded it · $4m
Short-term liabilities $2mLonger-term liabilities $0mShareholders' equity $3m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $149,176 of longer-dated liabilities.
  • More cash than debt $1m of cash against $152,033 of debt.
  • Debt below 40% of shareholders' equity Debt is 6% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$9m of operating cash flow against $152,033 of debt.
  • Operating profit covers interest at least five times over Operating income of −$9m against $7,586 of interest.

From 60 Degrees Pharmaceuticals, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
209.6%
of revenue
Days sales outstanding
186 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated SXTP SXTC SCNX LPCN NTRB EYPT Median
Revenue, last 12 months $1m $1m $821315 $2m $2m $3m $276m
Revenue growth, last 12 months 73.2% −34.6% 540.6% −62.7% −37.3% −94.6% 9.9%
Revenue growth, 3-year average 74.9% — −58.5% 205.6% −10.8% −57.9% 5.5%
Revenue growth, latest quarter 106.0% — 449.1% −69.5% −29.7% −90.5% 6.5%
Gross margin 19.4% 21.9% 87.7% — 33.1% — 62.0%
Operating margin −774.9% −625.9% <−999% −800.8% −435.6% <−999% −5.9%
Operating margin, 3-year average <−999% −267.4% <−999% −378.5% −396.6% <−999% −7.4%
Net margin −729.9% −545.2% <−999% −755.1% −430.4% <−999% −7.3%
Cash from operations / revenue −789.8% −353.0% <−999% −713.0% −224.5% <−999% 10.2%
Free-cash-flow margin −800.6% −353.0% <−999% −713.0% −224.5% <−999% 8.6%
Free-cash-flow margin, 3-year average — −126.6% <−999% −309.9% −217.5% <−999% 7.4%
Stock pay / revenue 37.2% 466.2% 257.1% 14.6% 65.9% >999% 3.6%
Change in share count — >999% 2.1% 25.2% 8.9% 4.2% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 73.2% 10.0% 6 of 74
Change in growth rate Growth +22.3pp -0.3pp 5 of 74
Gross margin Profitability 19.4% 59.8% 52 of 59
Operating margin Profitability -774.9% -5.9% 60 of 67
Net margin Profitability -729.9% -7.3% 69 of 75
Free-cash-flow margin Cash generation -800.6% 10.1% 69 of 74
Stock pay as % of revenue Cash generation 37.2% 3.6% 63 of 69
Long-term debt as % of assets Balance sheet 3.5% 23.8% 11 of 53
Days sales outstanding Balance sheet 186 days 72 days 53 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$614,803
Institutions reporting
8
Shares held vs prior quarter
▲ 79.8%
Positions opened / closed
3 / 3

Top buyers and sellers, Q2 2026: 4 institutions bought and 6 sold ; the biggest buyer was Kathmere Capital Management, LLC (+120K shares) and the biggest seller UBS Group AG (−18K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Kathmere Capital Management, LLC $466,576 265K 75.9% ▲ 83.2%
Citadel Advisors LLC $39,357 22K 6.4% New
Xtx Topco Ltd $31,045 18K 5.0% New
Kovack Advisors, Inc. $26,400 15K 4.3% New
Geode Capital Management, LLC $25,608 15K 4.2% ▼ 10.7%
UBS Group AG $23,922 14K 3.9% ▼ 56.7%
Barclays PLC $1,851 1K 0.3% ▼ 43.3%
Osaic Holdings, Inc. $44 0K 0.0% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not 60 Degrees Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $30,085 4 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $30,085 net buying
Insider Date Trade Shares Price Value
Dow Geoffrey S President and CEO June 12, 2026 Buy 7,350 $1.38 $10,143
Dow Geoffrey S President and CEO December 15, 2025 Buy 9,670 $0.80 $7,736
Dow Geoffrey S President and CEO December 11, 2025 Buy 3,613 $0.92 $3,324
Dow Geoffrey S President and CEO December 10, 2025 Buy 9,350 $0.95 $8,882

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on 60 Degrees Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

60 Degrees Pharmaceuticals, Inc. in brief

What does 60 Degrees Pharmaceuticals, Inc. do?
60 Degrees Pharmaceuticals, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is 60 Degrees Pharmaceuticals, Inc.'s stock ticker?
60 Degrees Pharmaceuticals, Inc. trades under the ticker SXTP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is 60 Degrees Pharmaceuticals, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, 60 Degrees Pharmaceuticals, Inc. reported revenue of $1.1M, 73.2% higher than a year earlier, according to its SEC filings.
What is 60 Degrees Pharmaceuticals, Inc.'s free cash flow?
60 Degrees Pharmaceuticals, Inc.'s free-cash-flow margin is -800.6% of revenue over the trailing twelve months, ranking 69 of the 74 pharmaceuticals companies we cover.
Who are 60 Degrees Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Kathmere Capital Management, LLC, Citadel Advisors LLC and Xtx Topco Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is 60 Degrees Pharmaceuticals, Inc.'s market cap?
On December 31, 2025, 60 Degrees Pharmaceuticals, Inc.'s market capitalisation was about $1.4M and net debt of -$1.4M. Market figures come from third-party market data and may be delayed.
How much debt does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc.'s debt-to-equity ratio is 5.8%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are 60 Degrees Pharmaceuticals, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to 60 Degrees Pharmaceuticals, Inc. are China SXT Pharmaceuticals, Inc., Scienture Holdings, Inc., Lipocine Inc., Nutriband Inc. and Eyepoint, Inc. The side-by-side comparison below sets their revenue, margins and growth against 60 Degrees Pharmaceuticals, Inc.'s.
Are insiders buying or selling 60 Degrees Pharmaceuticals, Inc. stock?
Over the last 12 months, 60 Degrees Pharmaceuticals, Inc.'s directors and officers reported 4 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.